Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies

Trial Profile

Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs WT 2725 (Primary)
  • Indications Acute myeloid leukaemia; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Interim results (n=62) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top